Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France

  1. Nicolas Germain
  2. Stéphanie Herwegh
  3. Anne-Sophie Hatzfeld
  4. Laurence Bocket
  5. Brigitte Prévost
  6. Pierre-Marie Danzé
  7. Philippe Marchetti

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.09.11.20192518: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethics statement: This study was performed according to the Declaration of Helsinki and approved by the Medical Ethical Committee of the CHU de Lille.
    Consent: Written informed consent forms were obtained from all enrolled living donors.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Analysis of anti-SARS-CoV-2 antibodies: Archived blood specimens collected on the day of donation for donor screening of infectious diseases were retrospectively tested for SARS-CoV-2 antibodies (Fig.2).
    SARS-CoV-2
    suggested: None
    The SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) (Batch #17298FN00, controls batch #17100FN00 and #17531FN00, Abbott, Illinois, USA) is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid (N) protein of SARS-CoV-2.
    immunoglobulin class G (IgG
    suggested: None
    The Wantai SARS-CoV-2 Ab is an enzyme-linked immunosorbent assays (ELISA) in a 96-well-plate format detecting total antibodies (including IgM and IgG) binding SARS-CoV-2 spike protein receptor binding domain (RBD).
    SARS-CoV-2 spike protein receptor binding domain ( RBD) .
    suggested: None
    Software and Algorithms
    SentencesResources
    The SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) (Batch #17298FN00, controls batch #17100FN00 and #17531FN00, Abbott, Illinois, USA) is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid (N) protein of SARS-CoV-2.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    External positive controls and donor samples were analyzed on an Abbott Architect i2000SR according to the manufacturer’s instructions.
    Abbott Architect
    suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1007/s10561-021-09901-3
  3. Version published to 10.1101/2020.09.11.20192518 on medRxiv